Literature DB >> 21834755

L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells.

S Tardito1, M Chiu, J Uggeri, A Zerbini, F Da Ros, V Dall'Asta, G Missale, O Bussolati.   

Abstract

Selected oncogenic mutations support unregulated growth enhancing glutamine availability but increasing the dependence of tumor cells on the amino acid. Data from literature indicate that a subset of HepatoCellular Carcinomas (HCC) is characterized by mutations of β-catenin and overexpression of Glutamine Synthetase (GS). To assess if this phenotype may constitute an example of glutamine addiction, we treated four human HCC lines with the enzyme L-Asparaginase (ASNase), a glutaminolytic drug. ASNase had a significant antiproliferative effect only in the β-catenin mutated HepG2 cells, which were partially rescued by the anaplerotic intermediates pyruvate and α-ketoglutarate. The enzyme severely depleted cell glutamine, caused eIF2α phosphorylation, inhibited mTOR activity, and increased autophagy in both HepG2 and in the β-catenin wild type cell line Huh-7. When used with ASNase, the GS inhibitor methionine sulfoximine (MSO) emptied cell glutamine pool, arresting proliferation in ASNase-insensitive Huh-7 cells and activating caspase-3 and apoptosis in HepG2 cells. Compared with Huh-7 cells, HepG2 cells accumulated much higher levels of glutamine and MSO, due to the higher expression and activity of SNAT2, a concentrative transporter for neutral amino acids, but were much more sensitive to glutamine withdrawal from the medium. In the presence of ASNase, MSO caused a paradoxical maintenance of rapamycin-sensitive mTOR activity in both HepG2 and Huh-7 cells. β-catenin silencing lowered ASNase sensitivity of HepG2 cells and of Huh-6 cells, another β-catenin-mutated cell line, which also exhibited high sensitivity to ASNase. Thus, β-catenin mutated HCC cells are more sensitive to glutamine depletion and accumulate higher levels of GS inhibitors. These results indicate that glutamine deprivation may constitute a targeted therapy for β-catenin-mutated HCC cells addicted to the amino acid.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21834755     DOI: 10.2174/156800911797264725

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  22 in total

1.  Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.

Authors:  Evan Delgado; Hirohisa Okabe; Morgan Preziosi; Jacquelyn Olivia Russell; Tamara Feliciano Alvarado; Michael Oertel; Kari Nichole Nejak-Bowen; Yixian Zhang; Satdarshan P S Monga
Journal:  J Hepatol       Date:  2014-10-18       Impact factor: 25.083

2.  Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Authors:  Lise Willems; Nathalie Jacque; Arnaud Jacquel; Nathalie Neveux; Thiago Trovati Maciel; Mireille Lambert; Alain Schmitt; Laury Poulain; Alexa S Green; Madalina Uzunov; Olivier Kosmider; Isabelle Radford-Weiss; Ivan Cruz Moura; Patrick Auberger; Norbert Ifrah; Valérie Bardet; Nicolas Chapuis; Catherine Lacombe; Patrick Mayeux; Jérôme Tamburini; Didier Bouscary
Journal:  Blood       Date:  2013-09-06       Impact factor: 22.113

3.  Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice.

Authors:  Junyan Tao; Rong Zhang; Sucha Singh; Minakshi Poddar; Emily Xu; Michael Oertel; Xin Chen; Shanthi Ganesh; Marc Abrams; Satdarshan P Monga
Journal:  Hepatology       Date:  2017-02-06       Impact factor: 17.425

Review 4.  The role of FAK in tumor metabolism and therapy.

Authors:  Jianliang Zhang; Steven N Hochwald
Journal:  Pharmacol Ther       Date:  2013-12-09       Impact factor: 12.310

5.  β-Catenin knockdown in liver tumor cells by a cell permeable gamma guanidine-based peptide nucleic acid.

Authors:  Evan Delgado; Raman Bahal; Jing Yang; Jung M Lee; Danith H Ly; Satdarshan P S Monga
Journal:  Curr Cancer Drug Targets       Date:  2013-10       Impact factor: 3.428

Review 6.  An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.

Authors:  Javier De Las Heras; Luis Aldámiz-Echevarría; María-Luz Martínez-Chantar; Teresa C Delgado
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-11-28       Impact factor: 4.481

7.  Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.

Authors:  Junyan Tao; Emily Xu; Yifei Zhao; Sucha Singh; Xiaolei Li; Gabrielle Couchy; Xin Chen; Jessica Zucman-Rossi; Maria Chikina; Satdarshan P S Monga
Journal:  Hepatology       Date:  2016-05-28       Impact factor: 17.425

Review 8.  Glutaminase regulation in cancer cells: a druggable chain of events.

Authors:  William P Katt; Richard A Cerione
Journal:  Drug Discov Today       Date:  2013-10-16       Impact factor: 7.851

9.  ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment.

Authors:  Martina Chiu; Giuseppe Taurino; Erica Dander; Donatella Bardelli; Alessandra Fallati; Roberta Andreoli; Massimiliano G Bianchi; Cecilia Carubbi; Giulia Pozzi; Laura Galuppo; Prisco Mirandola; Carmelo Rizzari; Saverio Tardito; Andrea Biondi; Giovanna D'Amico; Ovidio Bussolati
Journal:  Blood Adv       Date:  2021-12-14

10.  Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma.

Authors:  B Zhang; L-W Dong; Y-X Tan; J Zhang; Y-F Pan; C Yang; M-H Li; Z-W Ding; L-J Liu; T-Y Jiang; J-H Yang; H-Y Wang
Journal:  Br J Cancer       Date:  2013-06-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.